 | Up a level |
Safroneeva, E; Coslovsky, Michael; Kuehni, C E; Zwahlen, M; Haas, N. A.; Panczak, R; Taft, T H; Hirano, I; Dellon, E S; Gonsalves, N; Leung, J; Bussmann, C; Woosley, J T; Yan, P; Romero, Y; Furuta, G T; Gupta, S K; Aceves, S S; Chehade, M; Straumann, A; ... (2015). Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity. Alimentary pharmacology & therapeutics, 42(8), pp. 1000-1010. Wiley-Blackwell 10.1111/apt.13370
Straumann, A; Conus, S; Grzonka, P; Kita, H; Kephart, G; Bussmann, C; Beglinger, C; Smith, D A; Patel, J; Byrne, M; Simon, H-U (2010). Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut, 59(1), pp. 21-30. London: BMJ Publishing Group 10.1136/gut.2009.178558
Schoepfer, AM; Bussmann, C; Zuber, M; Vannini, S; Straumann, A (2007). Procedure-induced Perforations and spontaneous ruptures in Eosinophilic Esophagitis: A Case Series and Review of the Literature. Schweizerisches Medizin-Forum SMF / Swiss medical forum / Forum médical suisse FMS, 7(Suppl. 38), 8S. Basel: EMH Editores Medicorum Helveticorum
